Marijuana Moment: Trump’s Cannabis Rescheduling Move Alone Won’t Stabilize The Industry Without Insurance Reimbursement Reform (Op-Ed)

[Tokeativity]

“A stable cannabis industry requires more than tax normalization. It requires integration into healthcare infrastructure that governs how therapeutic products are accessed, financed and sustained.”

By Gennaro Luce and Matthew Myro Rothman, CannaLnx

Momentum around federal cannabis reform has shifted. Following President Donald Trump’s executive order directing the rescheduling of cannabis, investors have interpreted the move as a meaningful step toward normalization. Multistate operators are accelerating acquisitions. Capital markets are cautiously reengaging. Optimism is back in the headlines.

Rescheduling would be significant. But it will not, by itself, stabilize the cannabis industry.

Moving cannabis from Schedule I to Schedule III would ease one of the most punishing structural burdens operators face: Section 280E of the Internal Revenue Code. Relief from 280E would improve margins, unlock cash flow and potentially make the sector more attractive to institutional investors. That is not trivial.

But 280E reform addresses taxation. It does not address integration or infrastructure.

The cannabis industry’s deeper instability is not simply a tax problem. It is a structural demand problem rooted in the fact that cannabis remains overwhelmingly an out-of-pocket purchase—even when used for medical purposes.

Rescheduling does not automatically create reimbursement pathways. It does not authorize or compel Medicare, Medicaid or commercial insurers to recognize cannabis as a covered therapeutic. It does not establish billing codes, claims infrastructure, validation mechanisms or federal guidance for employer-sponsored health plans.

And it does not change the reality that most medical cannabis patients today must pay entirely out of pocket.

As long as cannabis remains a cash-based retail product, its market dynamics will resemble consumer discretionary goods—not health care.

That distinction matters.

Out-of-pocket markets are inherently price-sensitive. They are vulnerable to discounting cycles, promotional churn, pricing inconsistency, lack of standards and illicit market competition. Patient retention is fragile when therapy depends on weekly or monthly cash flow rather than structured and reliable benefit coverage. In that environment, consolidation may create larger operators. But it does not foster durable demand.

Recent M&A activity reflects renewed confidence following rescheduling signals. But consolidation in a cash-based system often magnifies structural weaknesses. Larger footprints still compete for the same out-of-pocket consumer. Expanded delivery networks still rely on the same price-driven acquisition tactics. Without structural changes to how medical cannabis is accessed and financed, scale alone does not change the underlying economics.

Health care markets behave differently.

When therapies are integrated into benefit systems, demand stabilizes. Patient access is mediated through structured pipelines rather than retail foot traffic. Benefits and reimbursement frameworks encourage continuity of care. Claims systems normalize repeat engagement. Price sensitivity shifts when costs are partially offset through employer-sponsored or insurer-backed benefit programs.

That infrastructure—not simply federal rescheduling—is what distinguishes a retail market from a health care-adjacent one.

To be clear, rescheduling could create downstream opportunities for research expansion, physician comfort and broader regulatory clarity. Those developments may gradually influence payer behavior. But none of them automatically generate reimbursement and benefit mechanisms.

Without deliberate policy movement toward benefit integration, cannabis will remain caught between two identities: treated as medicine by patients, but treated as a consumer good by federal health systems.

This liminal status creates volatility.

Operators continue to navigate compressed margins, price competition and retention challenges not solely because of tax burdens, but because medical cannabis lacks the institutional support systems that anchor other therapeutic categories. In most states, medical programs operate independently from federal health care frameworks. Employers that choose to support medical cannabis reimbursement do so through patchwork arrangements rather than standardized guidance. Payers face ambiguity about compliance, coding and risk exposure—and delay their entry.

Rescheduling does not resolve that ambiguity.

If policymakers intend for cannabis to evolve into a health care-adjacent market, reform cannot stop at tax relief. Clear federal guidance on reimbursement pathways, claims administration and benefit integration would do more to stabilize long-term demand than scale-driven consolidation alone.

Otherwise, the industry risks a familiar cycle: regulatory optimism, acquisition waves, margin pressure and retrenchment.

Rescheduling may reduce friction. But without reimbursement reform, it does not redesign the system to meet the needs of patients dependent on these valuable therapeutics.

A stable cannabis industry requires more than tax normalization. It requires integration into healthcare infrastructure that governs how therapeutic products are accessed, financed and sustained. Until the stage is set for such integration, consolidation will expand footprints—but won’t strengthen foundations.

Gennaro Luce is the CEO of CannaLnx by EM2P2, the first HIPAA-compliant digital platform that connects patients, doctors, dispensaries and healthcare payers. Matthew Myro Rothman is the company’s Chief Science Officer.

The post Trump’s Cannabis Rescheduling Move Alone Won’t Stabilize The Industry Without Insurance Reimbursement Reform (Op-Ed) appeared first on Marijuana Moment.

View the live link on MarijuanaMoment.net